The recent wide availability of biosynthetic human growth hormone (bio-HGH) obtained by DNA recombinant technique has led many authors to attempt GH therapeutical trials in conditions different from 'classical' GH deficiency. Encouraging results have been observed in girls with Turner's syndrome even though data on the final height of these patients have not been provided until now. Doubtful or negative results have been obtained in patients with Down's syndrome, Russel's syndrome, Noonan's syndrome, and in subjects with constitutional growth delay. Since no conclusive data are available on the efficacy and safety of GH use in conditions different from hypopituitarism, the only certain indication of GH therapy remains the treatment of GH deficiency. Laboratory evaluation of GH deficiency can be performed by various pharmacological stimulation tests (total deficiency: GH peak responses <5 ng/ml; partial deficiency: peak responses between 5 and 10 ng/ml). GHRH test may be useful in differentiating a hypothalamic from a pituitary deficiency. Finally, insulin-like growth factor I evaluation is not sufficiently reliable to substitute other tests in the assessment of pituitary function.
|Number of pages||6|
|Journal||Medicina - Rivista della Enciclopedia Medica Italiana|
|Publication status||Published - 1988|
ASJC Scopus subject areas